AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 — Update

By Billy Gray

AstraZeneca expects continued sales growth this year and restated its ambitious 2030 revenue target of $80 billion as it posted a surge in emerging-market results.

The British drugmaker said it anticipates 2026 revenue to grow at constant exchange rates by a mid-to-high single-digit percentage, and core earnings per share to climb by a low double-digit percentage.

Chief Executive Officer Pascal Soriot said in a call with reporters on Tuesday that the group's confidence in reaching $80 billion in revenue in 2030 was growing. Some analysts were skeptical of that goal when it was announced two years ago, and meeting it would depend in large part on sustained pipeline success.

AstraZeneca counts 16 blockbuster treatments in its portfolio, and that pipeline momentum will continue into 2026, it said. The company has more than 100 ongoing late-phase trials for drug candidates.

Notable treatment candidates include Elecoglipron, an oral obesity drug that the group said would proceed to late-phase trials in its results update.

A number of pharma players are aiming to enter the fast-growing obesity drug market currently led by Eli Lilly and Novo Nordisk. AstraZeneca said one of its objectives is for its obesity portfolio to improve the quality of weight-loss by, for instance, reducing muscle-mass deterioration. There's unmet potential for obesity drugs in emerging markets, it added.

AstraZeneca said performance across geographies was a highlight of the earnings update and that revenue last year jumped 22% at constant currency in emerging markets excluding China. U.S. sales rose 10%, and EU revenue grew 1% at constant exchange rates.

The pharmaceutical major on Tuesday posted fourth-quarter revenue of $15.50 billion, compared with $14.89 billion for the prior-year period. Analysts saw revenue at $15.505 billion, according to consensus estimates compiled by Visible Alpha.

Core earnings per share--the company's preferred metric, which strips out exceptional and other one-off items--were $2.12, up from $2.09. Analysts had forecast $2.11.

Write to Billy Gray at william.gray@wsj.com

(END) Dow Jones Newswires

February 10, 2026 06:41 ET (11:41 GMT)